How many courses of upatinib treatment are needed to treat eczema?

Upadacitinib is a JAK1 selective inhibitor that is widely used to treat immune-related skin diseases such as atopic dermatitis (eczema). For patients with atopic dermatitis, upadatinib can effectively relieve symptoms of itching, redness, swelling and skin damage, and improve the patient's quality of life. However, the specific course and length of treatment depend on the severity of the individual's condition, response to medications, and the doctor's treatment plan.

Normally, the initial course of treatment with upadatinib for the treatment of eczema requires at least 8 to 12 weeks, that is, about 2 to 3 months to observe the patient's response to the drug and improvement of symptoms. According to clinical research results and treatment guidelines, many patients can see significant improvements in symptoms during this time period, such as reduced itching and reduced skin inflammation. However, atopic dermatitis is a chronic relapsing disease, and patients may still need to continue treatment after initial improvement to further control the disease and prevent recurrence of symptoms.

In cases of severe or recurrent disease, doctors usually recommend that patients continue to use upadatinib for maintenance treatment after the initial course of treatment. The length of the maintenance course depends on the condition. The purpose of maintenance treatment is to further consolidate the efficacy and reduce the risk of disease recurrence after the initial effect is achieved. In this case, patients may need continued treatment for six months or more.

After some patients complete several courses of treatment, their condition is under long-term stable control. At this time, doctors may gradually reduce the dose of upadatinib or try to stop the medication. However, the decision to discontinue medication needs to be made under the guidance of a physician, and the condition should be closely monitored to prevent a recurrence of symptoms. If the condition recurs after stopping the medication, treatment may need to be restarted.

In addition, for patients with milder disease, the course of upadatinib treatment may be relatively short, and after symptoms are controlled, doctors may recommend topical treatment or other non-systemic drugs to maintain the condition.